National Academies Press: OpenBook

Initial National Priorities for Comparative Effectiveness Research (2009)

Chapter: Appendix A: Public Meeting Agenda - March 20, 2009

« Previous: 6 Essential Priorities for a Robust CER Enterprise
Suggested Citation:"Appendix A: Public Meeting Agenda - March 20, 2009." Institute of Medicine. 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press. doi: 10.17226/12648.
×
Page 167
Suggested Citation:"Appendix A: Public Meeting Agenda - March 20, 2009." Institute of Medicine. 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press. doi: 10.17226/12648.
×
Page 168
Suggested Citation:"Appendix A: Public Meeting Agenda - March 20, 2009." Institute of Medicine. 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press. doi: 10.17226/12648.
×
Page 169
Suggested Citation:"Appendix A: Public Meeting Agenda - March 20, 2009." Institute of Medicine. 2009. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press. doi: 10.17226/12648.
×
Page 170

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix A Public Meeting Agenda— March 20, 2009 COMMITTEE ON COMPARATIVE EFFECTIVENESS RESEARCH PRIORITIZATION PUBLIC AGENDA—FRIDAY, MARCH 20, 2009 FRIDAY, MARCH 20 —  PEN SESSION Stakeholder’s Presentations O — Auditorium 8:30am Welcome to Public Session (Dr. Sox) • Mechanisms of announcement (email, website) • Mechanisms of input (meeting and call-in presentations, web submissions) 9:00am Invited presentations from stakeholders • Myrl Weinberg, National Health Council • Nancy Nielsen, American Medical Association • Carmella Bocchino, America’s Health Insurance Plans • Ted Buckley, Biotechnology Industry Organization • Mary Jean Schumann, American Nurses Association • William Vaughan, Consumers Union • Ted Epperly, American Academy of Family Physicians • Randy Burkholder, Pharmaceutical Research and Manufacturers of America Question and Answer Session 167

168 INITIAL NATIONAL PRIORITIES FOR CER 10:00am • Naomi Aronson, Blue Cross/Blue Shield Association • Mohammad Akhter, National Medical Association • Dorothy Jeffress, Center for Advancement of Health • Robert Hall, American Academy of Pediatrics • Teresa Lee, Advanced Medical Technology Association • Antonio C. Wolff, American Society of Clinical Oncology • Jack Lewin, American College of Cardiology • Harold Miller, Network for Regional Healthcare Improvement Question and Answer Session 11:00am • Bryan Luce, United BioSource Corporation • Leah Hole-Curry, WA State Health Care Authority • Erick Turner, Oregon health and Science University and Portland VA Medical • Robert Harrison, California Dept of Public Health • Gary Puckrein, National Minority Quality Forum • Marilyn Dix Smith, International Society for Pharmacoeconomics & Outcomes Research • Frederick Grover, Society of Thoracic Surgeons • Douglas Hadley, CIGNA • Adolph Falcon, National Alliance for Hispanic Health • Roger Williams, United States Pharmacopeia Question and Answer Session 12:00pm Lunch Break 1:00pm • Nada Stotland, American Psychiatric Association • Ruth Lubic, Developing Families Center • William Weintraub, American Heart Association • Eugene Rich, Association of American Medical Colleges • Merrill Goozner, Center for Science in the Public Interest • Jeff Allen, Friends of Cancer Research • Les Paul, National Pharmaceutical Council • Steven Bailey, Society for Cardiovascular Angiography and Interventions Question and Answer Session 2:00pm • Clifford Goodman, The Lewin Group • Amy Abernethy, Duke University Medical Center • Katie Orrico, American Association of Neurological Surgeons

APPENDIX A 169 • Christopher Fox, American Association for Dental Research • Amy Miller, Personalized Medicine Coalition • Douglas Peddicord, Association of Clinical Research Organizations • Patrick O’Connor, HealthPartners Research Foundation • Janet Marchibroda, eHealth Initiative Question and Answer Session 3:00pm • J mes Bray, American Psychological Association a • C. Edwin Webb, American College of Clinical Pharmacy • Harrison Spencer, Association of Schools of Public Health • Andrew Sperling, National Alliance on Mental Illness • John Brooks, University of Iowa • Marty Makary, American College of Surgeons • Perry D. Cohen, Parkinson Pipeline Project • Morgan Downey, Health Care Consultancy • Dennis Hart, Focus On Therapeutic Outcomes, Inc. • Eunince K. M. Ernst, Frontier School of Midwifery & Family Nursing • Carolyn Curtis • Patrick O’Connor, American College of Occupational and Environmental Medicine Question and Answer Session 3:50pm Concluding remarks (Dr. Sox) 4:00pm Adjourn

Next: Appendix B: Stakeholder Questionnaire »
Initial National Priorities for Comparative Effectiveness Research Get This Book
×
Buy Paperback | $49.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Clinical research presents health care providers with information on the natural history and clinical presentations of disease as well as diagnostic and treatment options. In today's healthcare system, patients, physicians, clinicians and family caregivers often lack the sufficient scientific data and evidence they need to determine the best course of treatment for the patients' medical conditions. Initial National Priorities for Comparative Effectiveness Research(CER) is designed to fill this knowledge gap by assisting patients and healthcare providers across diverse settings in making more informed decisions. In this 2009 report, the Institute of Medicine's Committee on Comparative Effectiveness Research Prioritization establishes a working definition of CER, develops a priority list of research topics, and identifies the necessary requirements to support a robust and sustainable CER enterprise.

As part of the 2009 American Recovery and Reinvestment Act, Congress appropriated $1.1 billion in federal support of CER, reflecting legislators' belief that better decisions about the use of health care could improve the public's health and reduce the cost of care. The Committee on Comparative Effectiveness Research Prioritization was successful in preparing a list 100 top priority CER topics and 10 recommendations for best practices in the field.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!